Clinical trials recruiting for Hepatocellular Carcinoma (HCC)
15
Recruiting trials
26
US states with sites
20
Countries
13%
Accept healthy volunteers
Phase breakdown
Drugs and treatments being studied
| Intervention | Trials |
|---|---|
| 89Zr-TLX250 PET/CT | 1 |
| Bevacizumab | 1 |
| CBA-1205 Part 1 | 1 |
| CBA-1205 Part 2 | 1 |
| CBA-1205 Part 3 | 1 |
| CBA-1205 Part 4 | 1 |
| CBA-1205 Part 5 | 1 |
| Carvedilol | 1 |
| DDI Probe Cocktail | 1 |
| Docetaxel | 1 |
| Doxorubicin | 1 |
| Eribulin | 1 |
Where trials are recruiting (top US states)
| State | Recruiting trials |
|---|---|
| Arizona | 3 |
| California | 2 |
| Florida | 2 |
| Minnesota | 2 |
| New York | 2 |
| Ohio | 2 |
| Colorado | 1 |
| Connecticut | 1 |
| Delaware | 1 |
| Illinois | 1 |
| Indiana | 1 |
| Kentucky | 1 |
Top cities
Cleveland, Ohio 2Jacksonville, Florida 2New York, New York 2Rochester, Minnesota 2Scottsdale, Arizona 2Austin, Texas 1Baltimore, Maryland 1Boston, Massachusetts 1Celebration, Florida 1Charlottesville, Virginia 1
Self-screener
Recruiting trials
- 18F-T2 PET/CT Imaging for CAIX Positive Solid Tumors
- A Comparative Study of MRI and Ultrasound for Detection of Primary Hepatocellular Carcinoma, Body Composition and Risk Factors for Decompensation in Liver Cirrhosis
- A Noninvasive and Screening miRNA Signature for Gastrointestinal Cancer
- A Phase 1 and 2 Study of VMD-102 in Hepatocellular Carcinoma and Other Solid Tumors
- A Phase I, First in Human Study of CBA-1205, Anti-DLK1 Monoclonal Antibody in Patients With Advanced Solid Tumors, Hepatocellular Carcinoma (HCC), Melanoma, and Pediatric Cancer
- A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)
- Endoscopic Variceal Ligation vs Carvedilol for the Prevention of First Esophageal Variceal Bleeding in Patients With HCC
- Esophageal Varices Prophylaxis in Hepatocellular Carcinoma Treated With Atezolizumab and Bevacizumab
- Evaluating the roLe of Multiplexed PET Imaging in the Detection and Staging of hepatocellulaR Carcinoma and gAstro-entero-pancreatic Tumors
- Registry of Minimally Invasive Cancer Treatment Using Spectral Angio-CT Image Guidance
- Sapu003 in Advanced mTOR-sensitive Solid Tumors
- Scout Dose of Resin Microspheres
- Study Assessing PET Imaging With Zirconium-labelled Girentuximab in Patients With HCC, BTC or NEN
- Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
- To Evaluate the Safety, Tolerability, and Preliminary Efficacy of XH001 Injection as Adjuvant Therapy in Patients With High-risk Recurrent Solid Tumors
Related conditions
Trials recruiting for Hepatocellular Carcinoma (HCC) often also study these conditions. Each links to its own recruiting-trial list.
Lung cancer 2180Renal Cell Carcinoma (RCC) 10Pancreatic cancer 870Hypertension 1201Colorectal cancer 1359Melanoma 487Colorectal cancer 50Breast cancer 2239Urothelial Carcinoma (UC) 5Pancreatic Ductal Adenocarcinoma (PDAC) 32
Common questions
Are these trials free to join?
Study-related care in a clinical trial is usually provided at no cost to participants, and some trials reimburse travel. Costs vary by study - the trial team will explain what is and is not covered. Confirm this directly with them.
How do I know if I am eligible for Hepatocellular Carcinoma (HCC) trials?
Each trial lists inclusion and exclusion criteria. The screener above checks stated age and sex only. The full eligibility (your medical history, current medications, test results) is assessed by the study team. Open any trial to read its criteria, then contact the site.
Is this list complete?
No. For the full list, search ClinicalTrials.gov.